 |
| Jan van de Winkel |
The Danish biotech Genmab has won a $25 million milestone from its $1.1 billion collaboration deal with Johnson & Johnson ($JNJ) on the CD38 antibody daratumumab. The company said the milestone was triggered by progress on the Phase III study of the drug for multiple myeloma, which was awarded "breakthrough" status at the FDA. "Since our partnership with Janssen began in October 2012, we have made very significant progress with the development of daratumumab," says Genmab CEO Jan van de Winkel, "announcing 5 new clinical studies and reporting data from two ongoing studies in multiple myeloma." Release